Trial Profile

Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Olaptesed pegol (Primary) ; Pembrolizumab (Primary)
Indications Brain cancer; Glioblastoma
Focus Adverse reactions; Proof of concept
Acronyms GLORIA
Sponsors TME Pharma

31 Oct 2024 According to TME Pharma media release, the company is awarded Euro 2.4 Million German Federal Grant to support NOX-A12 phase 2 trial in Brain Cancer
24 Sep 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2028.
24 Sep 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com